AR133280A1 - TREM2 MODULATORS - Google Patents
TREM2 MODULATORSInfo
- Publication number
- AR133280A1 AR133280A1 ARP240101862A ARP240101862A AR133280A1 AR 133280 A1 AR133280 A1 AR 133280A1 AR P240101862 A ARP240101862 A AR P240101862A AR P240101862 A ARP240101862 A AR P240101862A AR 133280 A1 AR133280 A1 AR 133280A1
- Authority
- AR
- Argentina
- Prior art keywords
- trem2
- increasing
- expression levels
- subject
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de la fórmula (1A) o la fórmula (1B). Una composición farmacéutica que comprende un compuesto de acuerdo con una cualquiera de las reivindicaciones precedentes, o una sal farmacéuticamente aceptable del mismo, y uno o más portadores, excipientes y/o diluyentes farmacéuticamente aceptables. Un método para potenciar o aumentar la actividad de TREM2, tal como un método de uno o más de i) mejorar o activar la señalización de TREM2 a través de DAP12, ii) inducir la fosforilación de una quinasa que interactúa con el complejo de señalización TREM2 / DAP12, tales como, pero no limitadas a, Syk, ZAP70, PI3K, Erk, AKT y GSK3b, iii) aumentar los niveles de fosforilación inducida por TREM2 de la quinasa Syk, iv) aumentar los niveles de expresión, tal como niveles de expresión en el cerebro, de uno o más genes regulados por TREM2, y/o v) aumentar los niveles de expresión, tal como niveles de expresión en el cerebro, de uno o más genes regulados por TREM2 seleccionados del grupo que consiste en CXCL10, CCL2, CST7 y TMEM119; en un sujeto que lo necesita, tal como en un sujeto que tiene una enfermedad neurodegenerativa, comprendiendo dicho método administrar al sujeto un compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con una cualquiera de las reivindicaciones 1 a 28.A compound of formula (1A) or formula (1B). A pharmaceutical composition comprising a compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients and/or diluents. A method of enhancing or increasing TREM2 activity, such as a method of one or more of i) enhancing or activating TREM2 signaling through DAP12, ii) inducing phosphorylation of a kinase that interacts with the TREM2/DAP12 signaling complex, such as, but not limited to, Syk, ZAP70, PI3K, Erk, AKT, and GSK3b, iii) increasing the levels of TREM2-induced phosphorylation of the kinase Syk, iv) increasing the expression levels, such as expression levels in the brain, of one or more TREM2-regulated genes, and/or v) increasing the expression levels, such as expression levels in the brain, of one or more TREM2-regulated genes selected from the group consisting of CXCL10, CCL2, CST7, and TMEM119; in a subject in need thereof, such as in a subject having a neurodegenerative disease, said method comprising administering to the subject a compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 28.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23185890 | 2023-07-17 | ||
| EP24164145 | 2024-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133280A1 true AR133280A1 (en) | 2025-09-10 |
Family
ID=91959354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101862A AR133280A1 (en) | 2023-07-17 | 2024-07-17 | TREM2 MODULATORS |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR133280A1 (en) |
| AU (1) | AU2024294814A1 (en) |
| TW (1) | TW202517639A (en) |
| WO (1) | WO2025017059A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202208355A (en) * | 2020-05-04 | 2022-03-01 | 美商安進公司 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| CR20220559A (en) | 2020-05-04 | 2023-08-18 | Vigil Neuroscience Inc | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| IL308167A (en) * | 2021-05-04 | 2023-12-01 | Vigil Neuroscience Inc | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| WO2023086801A1 (en) * | 2021-11-09 | 2023-05-19 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
-
2024
- 2024-07-17 WO PCT/EP2024/070237 patent/WO2025017059A1/en active Pending
- 2024-07-17 AU AU2024294814A patent/AU2024294814A1/en active Pending
- 2024-07-17 TW TW113126753A patent/TW202517639A/en unknown
- 2024-07-17 AR ARP240101862A patent/AR133280A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202517639A (en) | 2025-05-01 |
| WO2025017059A1 (en) | 2025-01-23 |
| AU2024294814A1 (en) | 2025-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212303A1 (en) | AZA-HETEROBYCYCLIC MAT2A INHIBITORS AND METHODS OF USE IN THE TREATMENT OF CANCER | |
| CO2024001285A2 (en) | Tricyclic compounds as kras inhibitors | |
| CL2022003185A1 (en) | Midazopyrimidines and triazolopyrimidines as a2a/a2b inhibitors ((sol. div. 202002198) | |
| CL2022001739A1 (en) | Substituted tricyclic compounds | |
| CO2022005128A2 (en) | Antiviral prodrugs and formulations thereof | |
| AR102467A1 (en) | METHODS TO TREAT INFECTIONS BY VIRUS FILOVIRIDAE | |
| CL2019002167A1 (en) | Compound of formula (ic) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and its use in the treatment of familial dysautonomia by improving the marn joint. (divisional application 201701823.) | |
| ECSP088830A (en) | BENZOXAZOLE AND BENZOTIAZOLE SUBSTITUTED COMPOUNDS-6-O AND METHODS TO INHIBIT THE SIGNALING CSF-1R | |
| MX389700B (en) | PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) AND THEIR USES FOR CANCER TREATMENT. | |
| DOP2018000187A (en) | DERIVATIVES OF PIRAZOLO [1,5-A] PIRAZIN-4-ILO | |
| ECSP13012892A (en) | IMIDAZO [5,1-f] [1,2,4] TRIAZINS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| AR086357A1 (en) | INDAZOL DERIVATIVES ACTIVE SUBSTITUTES AS QUINASE INHIBITORS | |
| NI200700043A (en) | INHIBITORS OF RNA-DEPENDENT RNA POLYMERASE OF HEPATITIS C VIRUS AND COMPOSITIONS AND TREATMENTS USING THEM. | |
| CL2022000457A1 (en) | Triazolopyrimidines as a2a/a2b inhibitors. | |
| AR085219A1 (en) | 6-CICLOALQUIL-PIRAZOLOPIRIMIDINONAS FOR THE TREATMENT OF CNS DISORDERS | |
| CL2008002114A1 (en) | Compounds derived from 1- (2,3-dihydrobenzo [1,4] dioxin-2-ylmethyl) azacycles-3-substituted; pharmaceutical composition; and use of the compound for the treatment of a stress-propagated mental disorder, Parkinson's disease, schizophrenia, attention deficit disorder, obsessive compulsive disorder, psychosis, among others. | |
| UY33817A (en) | ? NEW BENCYLIC OXINDOLPIRIMIDINES ?. | |
| UY27924A1 (en) | FLUORATED DIARILURE TYPE COMPOUNDS | |
| AR075411A1 (en) | TRIAZOL DERIVATIVES [1,5-A] PYRIDINE AS KINASA INHIBITORS. | |
| AR127470A1 (en) | LRRK2 INHIBITORS | |
| AR104731A1 (en) | BENZAMIDS REPLACED AND METHODS TO USE THEM | |
| DOP2024000102A (en) | MACROCYCLIC COMPOUNDS WITH FARNESYLTRANSFERASE INHIBITORY ACTIVITY | |
| CL2013003646A1 (en) | Compounds derived from trans-1- (3s.1r) -6-chloro-3-phenylindan-1-yl) -1,2,2-trimethylpiperazine deuterated, with activity in the 5ht2, d1 and d2 receptors; Preparation process; intermediate compound; pharmaceutical composition and combination; and its use for the treatment of psychosis, among others. | |
| CO2024015229A2 (en) | Compounds and uses of these | |
| CL2016002749A1 (en) | A reduced composition in n-1 impurities comprising a polynucleotide compound linked by inter-subunit bonds of phosphoramidate n3-p5 or a pharmaceutically acceptable salt thereof and its synthesis method based on amino-dinucleotide dimers phosphoramidate-5-phosphoramidite -3 protected. |